Skip to main content
Updated:
Original:

U of M study finds hydroxychloroquine drug doesn't prevent COVID-19

President Donald Trump has touted the drug and said he takes it.

An anti-malaria drug President Donald Trump has touted and said he takes in hopes of preventing COVID-19 does not prevent the illness, a University of Minnesota Medical School study found

The study, which began March 17, was the first randomized clinical trial testing the drug, called hydroxychloroquine, to see if it could prevent the COVID-19 infection in a healthy person after they were exposed to someone with the illness. The U of M published the results in the New England Journal of Medicine on Wednesday.

“Our objective was to answer the question of whether hydroxychloroquine worked to prevent disease or did not work,” David Boulware, the senior investigator of the trial and infectious disease physician at the University of Minnesota, said in a news release. “While we are disappointed that this did not prevent COVID-19, we are pleased that we were able to provide a conclusive answer. Our objective was to find an answer.”

According to the U of M, hydroxychloroquine wasn't able to prevent the development of COVID-19 any better than a placebo. Approximately 12 percent of people given hydroxychloroquine developed COVID-19 versus approximately 14 percent given the vitamin placebo (folate), which the U of M says is not a statistical difference. 

The double-blind trial involved 821 non-hospitalized adults across the U.S. and Canada who were exposed to the virus from someone living in their home or as a healthcare worker or first responder. Half of the participants received five days of hydroxychloroquine and the other half took a placebo. 

The U of M said 40 percent of the people in the trial taking hydroxychloroquine developed non-serious side effects (nausea, upset stomach or diarrhea), and the trial found no serious side effects of taking the drug.

The findings of "no serious side effects" in the U of M study tallies with questions now being raised over a previous trial published in The Lancet last month, which said taking hydroxychloroquine for COVID-19 could result in a higher mortality rate.

On Thursday, The Lancet published a retraction after concerns were raised about the company carrying out the study. The WHO has now resumed its clinical trials into hydroxychloroquine.

Next Up

Cam Talbot / Minnesota Wild

Talbot leads Wild to 7th straight victory

The Wild opened a four-game road trip with a win in Edmonton.

Paige Bueckers

Paige Bueckers out 6-8 weeks with injury

The Hopkins native was hurt during Sunday's matchup with Notre Dame.

Anthony Barr

Vikings' defense could get reinforcements against Steelers

Several starters could return for a critical Thursday night matchup.

Mercer ATV accident fundraiser

High schooler in coma, fighting for his life after ATV crash

Family members found the teen on the ground and unresponsive.

Nolan Sprengeler - muskie record - nov 2021

Angler officially breaks 64-year-old state muskie record

The muskellunge he caught on Nov. 22 weighed a whopping 55 pounds, 14 ounces.

coronavirus, ICU, covid-19 hospital, doctor

4th teen COVID-19 death reported in MN is the 2nd in as many weeks

All four teenage COVID-19 deaths in the state have been reported in the past two months.

Anil Menon

Minnesota native named to NASA's new astronaut class

When he's done training, he could be sent to the space station or the moon.

broadway pizza interior facebook

Gallery: Original Broadway Pizza auctioning off everything

Get your hands on some classic Broadway signage, train-themed decor and more.

art shanty projects

Art Shanty Projects to return to Lake Harriet this winter

The festival has made some creative changes in response to the COVID-19 pandemic and climate change.

flickr - gov tim walz - mn senate dfl

After 'extraordinary' revenue growth, MN projects $7.7B surplus

But finance officials note there is still "significant risk" due to economic uncertainty.

Related

coronavirus

U of M study: Hydroxychloroquine shows no benefit in treating COVID-19

It was the first randomized clinical trial of hydroxychloroquine to treat non-hospitalized adults with COVID-19.

Michael Osterholm

U of M's Osterholm named to President-elect Biden's COVID-19 advisory board

The board has prominent doctors and scientists tasked at guiding Biden's transition to president and planning for the federal response to the virus.

University of minnesota sign

Big crowds at U of M 'Superblock' spark COVID-19 concerns

The U says it's reviewing video of the incident, but students say the university isn't doing enough to protect students.

010514-A-YG824-004

What's in the $2 trillion COVID-19 aid package passed by Congress?

The bill was signed off by President Donald Trump on Friday.

SARS-CoV-2, novel coronavirus

Minnesota reaches 700 COVID-19 deaths, ICU cases rising

Minnesota has now exceeded 700 deaths from the disease caused by the new coronavirus.

SARS-CoV-2, novel coronavirus

COVID-19's impact on African Americans in Minnesota

This week's episode discusses the social and healthcare impacts of the coronavirus on Minnesota's communities of color.

SARS-CoV-2, novel coronavirus

Coronavirus: 5 more deaths as the COVID-19 outbreak continues

The Centers for Disease Control & Prevention says COVID-19 is widespread in Minnesota.

coronavirus, covid-19, doctor

U of M, Mayo Clinic testing provides hope for Minnesota in COVID-19 fight

Both institutions are in the process of preparing to deploy the tests to the public.